Sarepta Therapeutics Inc. (SRPT)

79.99
NASDAQ : Health Technology
Prev Close 78.55
Day Low/High 77.67 / 80.87
52 Wk Low/High 28.82 / 84.37
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 64.98M
Market Cap 5.10B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

Big Cap Tech Was the Play of the Day

Big Cap Tech Was the Play of the Day

With few catalysts for the markets, Tuesday's special election for a Pennsylvania congressional seat could set the tone this week.

There's Plenty of Positive Action But It's a Little Overheated

There's Plenty of Positive Action But It's a Little Overheated

I'll be watching for entry points to develop this afternoon.

There's No Big Rush for the Indices at this Point

There's No Big Rush for the Indices at this Point

The best way to deal with the struggling market is selective stock picking and good defense.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

It is important to note that watching for a reversal is much different than being short.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

Duchenne Organizations Led by Parent Project Muscular Dystrophy Help Fund Next Step in Cutting-Edge Treatment

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

Stock Indexes Manage Another Day of Gains

Stock Indexes Manage Another Day of Gains

If you're not nervous, you're not paying attention.

TheStreet Quant Rating: D (Sell)